転移性抗がん剤のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Metastatic Cancer Drug Market Insights, Forecast to 2028

• レポートコード：QY2207E09252 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の転移性抗がん剤の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に転移性抗がん剤の世界市場のxxx％を占める「トラスツズマブ」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の転移性抗がん剤の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの転移性抗がん剤市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの転移性抗がん剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 転移性抗がん剤のグローバル主要メーカーには、AstraZeneca、Merck、Pfizer、Celgene、AKRON、Novartis、Galen、Pacira BioSciences、Johnson & Johnson、Fresenius Kabi AG、Spectrum Pharmaceuticals、Takeda Pharmaceutical、Teva Pharmaceutical Industries、Cipla、Sun Pharmaceutical Industries、Shanghai Fosun Pharmaceutical、Ingenusなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 転移性抗がん剤市場は、種類と用途によって区分されます。世界の転移性抗がん剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 トラスツズマブ、ペルツズマブ 【用途別セグメント】 病院、専門クリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 転移性抗がん剤製品概要 - 種類別市場（トラスツズマブ、ペルツズマブ） - 用途別市場（病院、専門クリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の転移性抗がん剤販売量予測2017-2028 - 世界の転移性抗がん剤売上予測2017-2028 - 転移性抗がん剤の地域別販売量 - 転移性抗がん剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別転移性抗がん剤販売量 - 主要メーカー別転移性抗がん剤売上 - 主要メーカー別転移性抗がん剤価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（トラスツズマブ、ペルツズマブ） - 転移性抗がん剤の種類別販売量 - 転移性抗がん剤の種類別売上 - 転移性抗がん剤の種類別価格 ・用途別市場規模（病院、専門クリニック） - 転移性抗がん剤の用途別販売量 - 転移性抗がん剤の用途別売上 - 転移性抗がん剤の用途別価格 ・北米市場 - 北米の転移性抗がん剤市場規模（種類別、用途別） - 主要国別の転移性抗がん剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの転移性抗がん剤市場規模（種類別、用途別） - 主要国別の転移性抗がん剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の転移性抗がん剤市場規模（種類別、用途別） - 主要国別の転移性抗がん剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の転移性抗がん剤市場規模（種類別、用途別） - 主要国別の転移性抗がん剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの転移性抗がん剤市場規模（種類別、用途別） - 主要国別の転移性抗がん剤市場規模（トルコ、サウジアラビア） ・企業情報 AstraZeneca、Merck、Pfizer、Celgene、AKRON、Novartis、Galen、Pacira BioSciences、Johnson & Johnson、Fresenius Kabi AG、Spectrum Pharmaceuticals、Takeda Pharmaceutical、Teva Pharmaceutical Industries、Cipla、Sun Pharmaceutical Industries、Shanghai Fosun Pharmaceutical、Ingenus ・産業チェーン及び販売チャネル分析 - 転移性抗がん剤の産業チェーン分析 - 転移性抗がん剤の原材料 - 転移性抗がん剤の生産プロセス - 転移性抗がん剤の販売及びマーケティング - 転移性抗がん剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 転移性抗がん剤の産業動向 - 転移性抗がん剤のマーケットドライバー - 転移性抗がん剤の課題 - 転移性抗がん剤の阻害要因 ・主な調査結果

Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms.
Market Analysis and Insights: Global Metastatic Cancer Drug Market
The global Metastatic Cancer Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Trastuzumab accounting for % of the Metastatic Cancer Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Metastatic Cancer Drug market size is valued at US$ million in 2021, while the North America and Europe Metastatic Cancer Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Metastatic Cancer Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metastatic Cancer Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metastatic Cancer Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metastatic Cancer Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metastatic Cancer Drug market.
Global Metastatic Cancer Drug Scope and Market Size
Metastatic Cancer Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Metastatic Cancer Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Trastuzumab
Pertuzumab
Segment by Application
Hospitals
Specialty Clinics
By Company
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

---

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Cancer Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Trastuzumab
1.2.3 Pertuzumab
1.3 Market by Application
1.3.1 Global Metastatic Cancer Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metastatic Cancer Drug Market Perspective (2017-2028)
2.2 Metastatic Cancer Drug Growth Trends by Region
2.2.1 Metastatic Cancer Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metastatic Cancer Drug Historic Market Size by Region (2017-2022)
2.2.3 Metastatic Cancer Drug Forecasted Market Size by Region (2023-2028)
2.3 Metastatic Cancer Drug Market Dynamics
2.3.1 Metastatic Cancer Drug Industry Trends
2.3.2 Metastatic Cancer Drug Market Drivers
2.3.3 Metastatic Cancer Drug Market Challenges
2.3.4 Metastatic Cancer Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metastatic Cancer Drug Players by Revenue
3.1.1 Global Top Metastatic Cancer Drug Players by Revenue (2017-2022)
3.1.2 Global Metastatic Cancer Drug Revenue Market Share by Players (2017-2022)
3.2 Global Metastatic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metastatic Cancer Drug Revenue
3.4 Global Metastatic Cancer Drug Market Concentration Ratio
3.4.1 Global Metastatic Cancer Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Cancer Drug Revenue in 2021
3.5 Metastatic Cancer Drug Key Players Head office and Area Served
3.6 Key Players Metastatic Cancer Drug Product Solution and Service
3.7 Date of Enter into Metastatic Cancer Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metastatic Cancer Drug Breakdown Data by Type
4.1 Global Metastatic Cancer Drug Historic Market Size by Type (2017-2022)
4.2 Global Metastatic Cancer Drug Forecasted Market Size by Type (2023-2028)
5 Metastatic Cancer Drug Breakdown Data by Application
5.1 Global Metastatic Cancer Drug Historic Market Size by Application (2017-2022)
5.2 Global Metastatic Cancer Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metastatic Cancer Drug Market Size (2017-2028)
6.2 North America Metastatic Cancer Drug Market Size by Type
6.2.1 North America Metastatic Cancer Drug Market Size by Type (2017-2022)
6.2.2 North America Metastatic Cancer Drug Market Size by Type (2023-2028)
6.2.3 North America Metastatic Cancer Drug Market Share by Type (2017-2028)
6.3 North America Metastatic Cancer Drug Market Size by Application
6.3.1 North America Metastatic Cancer Drug Market Size by Application (2017-2022)
6.3.2 North America Metastatic Cancer Drug Market Size by Application (2023-2028)
6.3.3 North America Metastatic Cancer Drug Market Share by Application (2017-2028)
6.4 North America Metastatic Cancer Drug Market Size by Country
6.4.1 North America Metastatic Cancer Drug Market Size by Country (2017-2022)
6.4.2 North America Metastatic Cancer Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Metastatic Cancer Drug Market Size (2017-2028)
7.2 Europe Metastatic Cancer Drug Market Size by Type
7.2.1 Europe Metastatic Cancer Drug Market Size by Type (2017-2022)
7.2.2 Europe Metastatic Cancer Drug Market Size by Type (2023-2028)
7.2.3 Europe Metastatic Cancer Drug Market Share by Type (2017-2028)
7.3 Europe Metastatic Cancer Drug Market Size by Application
7.3.1 Europe Metastatic Cancer Drug Market Size by Application (2017-2022)
7.3.2 Europe Metastatic Cancer Drug Market Size by Application (2023-2028)
7.3.3 Europe Metastatic Cancer Drug Market Share by Application (2017-2028)
7.4 Europe Metastatic Cancer Drug Market Size by Country
7.4.1 Europe Metastatic Cancer Drug Market Size by Country (2017-2022)
7.4.2 Europe Metastatic Cancer Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metastatic Cancer Drug Market Size (2017-2028)
8.2 Asia-Pacific Metastatic Cancer Drug Market Size by Type
8.2.1 Asia-Pacific Metastatic Cancer Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Metastatic Cancer Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Metastatic Cancer Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Metastatic Cancer Drug Market Size by Application
8.3.1 Asia-Pacific Metastatic Cancer Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Metastatic Cancer Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Metastatic Cancer Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Metastatic Cancer Drug Market Size by Region
8.4.1 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Metastatic Cancer Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metastatic Cancer Drug Market Size (2017-2028)
9.2 Latin America Metastatic Cancer Drug Market Size by Type
9.2.1 Latin America Metastatic Cancer Drug Market Size by Type (2017-2022)
9.2.2 Latin America Metastatic Cancer Drug Market Size by Type (2023-2028)
9.2.3 Latin America Metastatic Cancer Drug Market Share by Type (2017-2028)
9.3 Latin America Metastatic Cancer Drug Market Size by Application
9.3.1 Latin America Metastatic Cancer Drug Market Size by Application (2017-2022)
9.3.2 Latin America Metastatic Cancer Drug Market Size by Application (2023-2028)
9.3.3 Latin America Metastatic Cancer Drug Market Share by Application (2017-2028)
9.4 Latin America Metastatic Cancer Drug Market Size by Country
9.4.1 Latin America Metastatic Cancer Drug Market Size by Country (2017-2022)
9.4.2 Latin America Metastatic Cancer Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metastatic Cancer Drug Market Size (2017-2028)
10.2 Middle East & Africa Metastatic Cancer Drug Market Size by Type
10.2.1 Middle East & Africa Metastatic Cancer Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Metastatic Cancer Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Metastatic Cancer Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Metastatic Cancer Drug Market Size by Application
10.3.1 Middle East & Africa Metastatic Cancer Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Metastatic Cancer Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Metastatic Cancer Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Metastatic Cancer Drug Market Size by Country
10.4.1 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Metastatic Cancer Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Metastatic Cancer Drug Introduction
11.1.4 AstraZeneca Revenue in Metastatic Cancer Drug Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Metastatic Cancer Drug Introduction
11.2.4 Merck Revenue in Metastatic Cancer Drug Business (2017-2022)
11.2.5 Merck Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Metastatic Cancer Drug Introduction
11.3.4 Pfizer Revenue in Metastatic Cancer Drug Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Celgene
11.4.1 Celgene Company Details
11.4.2 Celgene Business Overview
11.4.3 Celgene Metastatic Cancer Drug Introduction
11.4.4 Celgene Revenue in Metastatic Cancer Drug Business (2017-2022)
11.4.5 Celgene Recent Developments
11.5 AKRON
11.5.1 AKRON Company Details
11.5.2 AKRON Business Overview
11.5.3 AKRON Metastatic Cancer Drug Introduction
11.5.4 AKRON Revenue in Metastatic Cancer Drug Business (2017-2022)
11.5.5 AKRON Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Metastatic Cancer Drug Introduction
11.6.4 Novartis Revenue in Metastatic Cancer Drug Business (2017-2022)
11.6.5 Novartis Recent Developments
11.7 Galen
11.7.1 Galen Company Details
11.7.2 Galen Business Overview
11.7.3 Galen Metastatic Cancer Drug Introduction
11.7.4 Galen Revenue in Metastatic Cancer Drug Business (2017-2022)
11.7.5 Galen Recent Developments
11.8 Pacira BioSciences
11.8.1 Pacira BioSciences Company Details
11.8.2 Pacira BioSciences Business Overview
11.8.3 Pacira BioSciences Metastatic Cancer Drug Introduction
11.8.4 Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2017-2022)
11.8.5 Pacira BioSciences Recent Developments
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Details
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Metastatic Cancer Drug Introduction
11.9.4 Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2017-2022)
11.9.5 Johnson & Johnson Recent Developments
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Details
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Metastatic Cancer Drug Introduction
11.10.4 Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2017-2022)
11.10.5 Fresenius Kabi AG Recent Developments
11.11 Spectrum Pharmaceuticals
11.11.1 Spectrum Pharmaceuticals Company Details
11.11.2 Spectrum Pharmaceuticals Business Overview
11.11.3 Spectrum Pharmaceuticals Metastatic Cancer Drug Introduction
11.11.4 Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2017-2022)
11.11.5 Spectrum Pharmaceuticals Recent Developments
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Details
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Metastatic Cancer Drug Introduction
11.12.4 Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022)
11.12.5 Takeda Pharmaceutical Recent Developments
11.13 Teva Pharmaceutical Industries
11.13.1 Teva Pharmaceutical Industries Company Details
11.13.2 Teva Pharmaceutical Industries Business Overview
11.13.3 Teva Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.13.4 Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022)
11.13.5 Teva Pharmaceutical Industries Recent Developments
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Metastatic Cancer Drug Introduction
11.14.4 Cipla Revenue in Metastatic Cancer Drug Business (2017-2022)
11.14.5 Cipla Recent Developments
11.15 Sun Pharmaceutical Industries
11.15.1 Sun Pharmaceutical Industries Company Details
11.15.2 Sun Pharmaceutical Industries Business Overview
11.15.3 Sun Pharmaceutical Industries Metastatic Cancer Drug Introduction
11.15.4 Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022)
11.15.5 Sun Pharmaceutical Industries Recent Developments
11.16 Shanghai Fosun Pharmaceutical
11.16.1 Shanghai Fosun Pharmaceutical Company Details
11.16.2 Shanghai Fosun Pharmaceutical Business Overview
11.16.3 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Introduction
11.16.4 Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022)
11.16.5 Shanghai Fosun Pharmaceutical Recent Developments
11.17 Ingenus
11.17.1 Ingenus Company Details
11.17.2 Ingenus Business Overview
11.17.3 Ingenus Metastatic Cancer Drug Introduction
11.17.4 Ingenus Revenue in Metastatic Cancer Drug Business (2017-2022)
11.17.5 Ingenus Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Metastatic Cancer Drug Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Trastuzumab
Table 3. Key Players of Pertuzumab
Table 4. Global Metastatic Cancer Drug Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Metastatic Cancer Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Metastatic Cancer Drug Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Metastatic Cancer Drug Market Share by Region (2017-2022)
Table 8. Global Metastatic Cancer Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Metastatic Cancer Drug Market Share by Region (2023-2028)
Table 10. Metastatic Cancer Drug Market Trends
Table 11. Metastatic Cancer Drug Market Drivers
Table 12. Metastatic Cancer Drug Market Challenges
Table 13. Metastatic Cancer Drug Market Restraints
Table 14. Global Metastatic Cancer Drug Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Metastatic Cancer Drug Revenue Share by Players (2017-2022)
Table 16. Global Top Metastatic Cancer Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2021)
Table 17. Ranking of Global Top Metastatic Cancer Drug Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Metastatic Cancer Drug Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Metastatic Cancer Drug Product Solution and Service
Table 21. Date of Enter into Metastatic Cancer Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Metastatic Cancer Drug Revenue Market Share by Type (2017-2022)
Table 25. Global Metastatic Cancer Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Metastatic Cancer Drug Revenue Market Share by Type (2023-2028)
Table 27. Global Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Metastatic Cancer Drug Revenue Share by Application (2017-2022)
Table 29. Global Metastatic Cancer Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Metastatic Cancer Drug Revenue Share by Application (2023-2028)
Table 31. North America Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Metastatic Cancer Drug Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Metastatic Cancer Drug Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Metastatic Cancer Drug Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Metastatic Cancer Drug Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Metastatic Cancer Drug Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Metastatic Cancer Drug Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Metastatic Cancer Drug Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Metastatic Cancer Drug Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Metastatic Cancer Drug Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Metastatic Cancer Drug Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Metastatic Cancer Drug Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Metastatic Cancer Drug Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Metastatic Cancer Drug Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Metastatic Cancer Drug Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Metastatic Cancer Drug Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Metastatic Cancer Drug Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Metastatic Cancer Drug Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Metastatic Cancer Drug Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Metastatic Cancer Drug Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Metastatic Cancer Drug Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Metastatic Cancer Drug Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Metastatic Cancer Drug Market Size by Country (2023-2028) & (US$ Million)
Table 61. AstraZeneca Company Details
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Metastatic Cancer Drug Product
Table 64. AstraZeneca Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 65. AstraZeneca Recent Developments
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck Metastatic Cancer Drug Product
Table 69. Merck Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 70. Merck Recent Developments
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer Metastatic Cancer Drug Product
Table 74. Pfizer Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 75. Pfizer Recent Developments
Table 76. Celgene Company Details
Table 77. Celgene Business Overview
Table 78. Celgene Metastatic Cancer Drug Product
Table 79. Celgene Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 80. Celgene Recent Developments
Table 81. AKRON Company Details
Table 82. AKRON Business Overview
Table 83. AKRON Metastatic Cancer Drug Product
Table 84. AKRON Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 85. AKRON Recent Developments
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Metastatic Cancer Drug Product
Table 89. Novartis Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 90. Novartis Recent Developments
Table 91. Galen Company Details
Table 92. Galen Business Overview
Table 93. Galen Metastatic Cancer Drug Product
Table 94. Galen Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 95. Galen Recent Developments
Table 96. Pacira BioSciences Company Details
Table 97. Pacira BioSciences Business Overview
Table 98. Pacira BioSciences Metastatic Cancer Drug Product
Table 99. Pacira BioSciences Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 100. Pacira BioSciences Recent Developments
Table 101. Johnson & Johnson Company Details
Table 102. Johnson & Johnson Business Overview
Table 103. Johnson & Johnson Metastatic Cancer Drug Product
Table 104. Johnson & Johnson Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 105. Johnson & Johnson Recent Developments
Table 106. Fresenius Kabi AG Company Details
Table 107. Fresenius Kabi AG Business Overview
Table 108. Fresenius Kabi AG Metastatic Cancer Drug Product
Table 109. Fresenius Kabi AG Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 110. Fresenius Kabi AG Recent Developments
Table 111. Spectrum Pharmaceuticals Company Details
Table 112. Spectrum Pharmaceuticals Business Overview
Table 113. Spectrum Pharmaceuticals Metastatic Cancer Drug Product
Table 114. Spectrum Pharmaceuticals Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 115. Spectrum Pharmaceuticals Recent Developments
Table 116. Takeda Pharmaceutical Company Details
Table 117. Takeda Pharmaceutical Business Overview
Table 118. Takeda Pharmaceutical Metastatic Cancer Drug Product
Table 119. Takeda Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 120. Takeda Pharmaceutical Recent Developments
Table 121. Teva Pharmaceutical Industries Company Details
Table 122. Teva Pharmaceutical Industries Business Overview
Table 123. Teva Pharmaceutical Industries Metastatic Cancer Drug Product
Table 124. Teva Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 125. Teva Pharmaceutical Industries Recent Developments
Table 126. Cipla Company Details
Table 127. Cipla Business Overview
Table 128. Cipla Metastatic Cancer Drug Product
Table 129. Cipla Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 130. Cipla Recent Developments
Table 131. Sun Pharmaceutical Industries Company Details
Table 132. Sun Pharmaceutical Industries Business Overview
Table 133. Sun Pharmaceutical Industries Metastatic Cancer Drug Product
Table 134. Sun Pharmaceutical Industries Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 135. Sun Pharmaceutical Industries Recent Developments
Table 136. Shanghai Fosun Pharmaceutical Company Details
Table 137. Shanghai Fosun Pharmaceutical Business Overview
Table 138. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Product
Table 139. Shanghai Fosun Pharmaceutical Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 140. Shanghai Fosun Pharmaceutical Recent Developments
Table 141. Ingenus Company Details
Table 142. Ingenus Business Overview
Table 143. Ingenus Metastatic Cancer Drug Product
Table 144. Ingenus Revenue in Metastatic Cancer Drug Business (2017-2022) & (US$ Million)
Table 145. Ingenus Recent Developments
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metastatic Cancer Drug Market Share by Type: 2021 VS 2028
Figure 2. Trastuzumab Features
Figure 3. Pertuzumab Features
Figure 4. Global Metastatic Cancer Drug Market Share by Application: 2021 VS 2028
Figure 5. Hospitals Case Studies
Figure 6. Specialty Clinics Case Studies
Figure 7. Metastatic Cancer Drug Report Years Considered
Figure 8. Global Metastatic Cancer Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 9. Global Metastatic Cancer Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Metastatic Cancer Drug Market Share by Region: 2021 VS 2028
Figure 11. Global Metastatic Cancer Drug Market Share by Players in 2021
Figure 12. Global Top Metastatic Cancer Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Cancer Drug as of 2021)
Figure 13. The Top 10 and 5 Players Market Share by Metastatic Cancer Drug Revenue in 2021
Figure 14. North America Metastatic Cancer Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 15. North America Metastatic Cancer Drug Market Size Market Share by Type (2017-2028)
Figure 16. North America Metastatic Cancer Drug Market Size Market Share by Application (2017-2028)
Figure 17. North America Metastatic Cancer Drug Market Size Share by Country (2017-2028)
Figure 18. United States Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Metastatic Cancer Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 21. Europe Metastatic Cancer Drug Market Size Market Share by Type (2017-2028)
Figure 22. Europe Metastatic Cancer Drug Market Size Market Share by Application (2017-2028)
Figure 23. Europe Metastatic Cancer Drug Market Size Share by Country (2017-2028)
Figure 24. Germany Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. France Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. U.K. Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Italy Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Russia Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Nordic Countries Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Metastatic Cancer Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 31. Asia Pacific Metastatic Cancer Drug Market Size Market Share by Type (2017-2028)
Figure 32. Asia Pacific Metastatic Cancer Drug Market Size Market Share by Application (2017-2028)
Figure 33. Asia Pacific Metastatic Cancer Drug Market Size Share by Region (2017-2028)
Figure 34. China Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 40. Latin America Metastatic Cancer Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 41. Latin America Metastatic Cancer Drug Market Size Market Share by Type (2017-2028)
Figure 42. Latin America Metastatic Cancer Drug Market Size Market Share by Application (2017-2028)
Figure 43. Latin America Metastatic Cancer Drug Market Size Share by Country (2017-2028)
Figure 44. Mexico Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Brazil Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Metastatic Cancer Drug Market Size YoY (2017-2028) & (US$ Million)
Figure 47. Middle East and Africa Metastatic Cancer Drug Market Size Market Share by Type (2017-2028)
Figure 48. Middle East and Africa Metastatic Cancer Drug Market Size Market Share by Application (2017-2028)
Figure 49. Middle East and Africa Metastatic Cancer Drug Market Size Share by Country (2017-2028)
Figure 50. Turkey Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Saudi Arabia Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. UAE Metastatic Cancer Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. AstraZeneca Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 54. Merck Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 55. Pfizer Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 56. Celgene Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 57. AKRON Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 58. Novartis Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 59. Galen Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 60. Pacira BioSciences Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 61. Johnson & Johnson Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 62. Fresenius Kabi AG Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 63. Spectrum Pharmaceuticals Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 64. Takeda Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 65. Teva Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 66. Cipla Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 67. Sun Pharmaceutical Industries Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 68. Shanghai Fosun Pharmaceutical Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 69. Ingenus Revenue Growth Rate in Metastatic Cancer Drug Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---